

S 1801

Affordable Medications Act

Congress: 116 (2019–2021, Ended)

Chamber: Senate

Policy Area: Health

Introduced: Jun 12, 2019

Current Status: Read twice and referred to the Committee on Finance.

Latest Action: Read twice and referred to the Committee on Finance. (Jun 12, 2019)

Official Text: <https://www.congress.gov/bill/116th-congress/senate-bill/1801>

Sponsor

Name: Sen. Smith, Tina [D-MN]

Party: Democratic • State: MN • Chamber: Senate

Cosponsors (15 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Baldwin, Tammy [D-WI]	D · WI		Jun 12, 2019
Sen. Blumenthal, Richard [D-CT]	D · CT		Jun 12, 2019
Sen. Booker, Cory A. [D-NJ]	D · NJ		Jun 12, 2019
Sen. Brown, Sherrod [D-OH]	D · OH		Jun 12, 2019
Sen. Durbin, Richard J. [D-IL]	D · IL		Jun 12, 2019
Sen. Gillibrand, Kirsten E. [D-NY]	D · NY		Jun 12, 2019
Sen. Hassan, Margaret Wood [D-NH]	D · NH		Jun 12, 2019
Sen. Klobuchar, Amy [D-MN]	D · MN		Jun 12, 2019
Sen. Merkley, Jeff [D-OR]	D · OR		Jun 12, 2019
Sen. Reed, Jack [D-RI]	D · RI		Jun 12, 2019
Sen. Sanders, Bernard [I-VT]	I · VT		Jun 12, 2019
Sen. Udall, Tom [D-NM]	D · NM		Jun 12, 2019
Sen. Warren, Elizabeth [D-MA]	D · MA		Jun 12, 2019
Sen. Whitehouse, Sheldon [D-RI]	D · RI		Jun 12, 2019
Sen. Harris, Kamala D. [D-CA]	D · CA		Sep 9, 2019

Committee Activity

Committee	Chamber	Activity	Date
Finance Committee	Senate	Referred To	Jun 12, 2019

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
116 HR 8399	Related bill	Sep 25, 2020: Referred to the House Committee on Ways and Means.
116 S 1785	Related bill	Jun 11, 2019: Read twice and referred to the Committee on Finance.
116 HR 1506	Related bill	Apr 8, 2019: Referred to the Subcommittee on Courts, Intellectual Property, and the Internet.
116 HR 1478	Related bill	Mar 1, 2019: Referred to the Subcommittee on Health.
116 HR 1093	Related bill	Feb 7, 2019: Referred to the Subcommittee on Health.
116 S 378	Related bill	Feb 7, 2019: Read twice and referred to the Committee on Finance.
116 HR 447	Related bill	Jan 25, 2019: Referred to the Subcommittee on Health.
116 S 73	Related bill	Jan 10, 2019: Read twice and referred to the Committee on Finance.
116 S 97	Related bill	Jan 10, 2019: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
116 S 64	Related bill	Jan 9, 2019: Read twice and referred to the Committee on the Judiciary.

Summary (as of Jun 12, 2019)

Affordable Medications Act

This bill revises and expands various requirements relating to prescription-drug pricing and affordability. Specifically, the bill

- expands financial reporting requirements for drug manufacturers and establishes corresponding civil penalties for noncompliance;
- adds reporting requirements for certain nonprofit patient-assistance programs;
- requires the Centers for Medicare & Medicaid Services (CMS) to negotiate prices for certain prescription drugs under Medicare;
- requires the Centers for Medicare and Medicaid Innovation within the CMS to test specified models for negotiating drug prices;
- establishes reporting requirements, and corresponding civil penalties for noncompliance, for pharmaceutical companies with respect to spikes in prescription-drug prices;
- establishes an excise tax on prescription drugs subject to price spikes;
- lessens prescription-drug cost-sharing requirements under qualified health plans and group health plans;
- modifies requirements for the importation of prescription drugs;
- requires drug manufacturers to provide drug rebates for drugs dispensed to certain low-income individuals under the Medicare program;
- limits the time frame that trade agreements are required to provide market exclusivity for biological products;
- establishes an innovation incentive fund for new or more effective treatments of bacterial infections;
- establishes a Center for Clinical Research within the National Institutes of Health;
- revises certain time frames and conditions related to drug exclusivity;
- requires the Food and Drug Administration to establish a database of generic drugs; and
- modifies other provisions related to generic drugs, prescription-drug advertising, disclosure of wholesale acquisition prices, and patent-infringement proceedings.

Actions Timeline

- **Jun 12, 2019:** Introduced in Senate
- **Jun 12, 2019:** Read twice and referred to the Committee on Finance.